Potential Expanded Indications for Neprilysin Inhibitors.

about

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.

P2860

Q42373826-BF452281-55A9-4AD5-802C-F3C3AF29DA9D

P2860

Potential Expanded Indications for Neprilysin Inhibitors.

Item

http://www.wikidata.org/entity/Q38747742

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Potential Expanded Indications for Neprilysin Inhibitors.

@en

type

Item

label

Potential Expanded Indications for Neprilysin Inhibitors.

@en

prefLabel

Potential Expanded Indications for Neprilysin Inhibitors.

@en

P1476

Potential Expanded Indications for Neprilysin Inhibitors.

@en

P2093

Elizabeth Riddell

http://www.w3.org/2001/XMLSchema#string

Justin M Vader

http://www.w3.org/2001/XMLSchema#string

P2860

2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease

Effect of nesiritide in patients with acute decompensated heart failure

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data.

Telmisartan, ramipril, or both in patients at high risk for vascular events.

Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease.

Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure.

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

P2888

s11897-017-0327-y

P304

134-145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11897-017-0327-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084033357

http://www.w3.org/2001/XMLSchema#string

P698

28281174

http://www.w3.org/2001/XMLSchema#string

P932

5645149

http://www.w3.org/2001/XMLSchema#string

Potential Expanded Indications for Neprilysin Inhibitors.

about

P2860

P2860

Potential Expanded Indications for Neprilysin Inhibitors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932